Beyond the 5%: Breaking Europe’s Decade of Rare Disease Stagnation

In late January 2026, a familiar yet unsettling statistic echoed through the halls of European health ministries: only 5% of rare diseases have an effective, approved treatment. This figure, cited in the U.K. Government’s 2025 Rare Diseases Action Plan, is identical to the one reported in The Pharmaceutical Journal nearly ten years ago. For the 3.5 million people in the U.K. and 30 million across Europe living with rare conditions, “progress” has long felt like a semantic exercise.

However, as of 2026, the European “red tape” is finally being rewritten to address a fundamental truth: you cannot regulate a cure for ten patients using the same rulebook built for ten million.

The Economic Pivot: NICE and the QALY Revolution

The most tangible shift began in the U.K. in December 2025, when the National Institute for Health and Care Excellence (NICE)—the body that decides which drugs are “value for money” for the NHS—announced its first cost-effectiveness threshold increase since 1999.

Starting April 2026, the standard threshold will rise from £20,000–£30,000 to £25,000–£35,000 (approx. $34,200–$47,900).

This move is critical because modern “orphan drugs” are often Advanced Therapy Medicinal Products (ATMPs)—complex cell and gene therapies. Unlike a daily pill for blood pressure, these are often “one-shot” treatments that carry high upfront manufacturing costs but save the system millions in lifetime care. By raising the ceiling, NICE is acknowledging that a curative gene therapy for Spinal Muscular Atrophy (SMA) or Haemophilia cannot be priced like a generic statin.

The Patient Paradox: Why Rare is So Difficult

To understand why the 5% figure is so stubborn, one must look at the unique anatomy of a rare disease. By definition, these conditions affect fewer than 1 in 2,000 people, but 80% are genetic in origin and half start in childhood.

The primary hurdle isn’t just a lack of money; it is a fragmentation of information. Because patients are so geographically dispersed, researchers often lack “natural history” data—the basic understanding of how a disease progresses over time without treatment. Without this baseline, it is impossible to prove a drug is actually working. Furthermore, the industry suffers from “data silos” where genomic banks and clinical registries in different countries don’t “talk” to each other, forcing scientists to reinvent the wheel for every new trial.

Regulatory Overhaul: The MHRA’s New Rulebook

Parallel to broader economic shifts, the Medicines and Healthcare products Regulatory Agency (MHRA)—the U.K.’s standalone regulator following Brexit—is overhauling its regulatory framework. As the executive agency responsible for ensuring the safety and effectiveness of medicines and medical devices, the MHRA is repositioning itself in 2026 from a strict regulatory “gatekeeper” to a more active enabler of innovation.

This shift comes against a sobering backdrop. Despite being labelled “rare,” the MHRA estimates that around 3.5 million people—approximately 1 in 17 in the U.K.—are affected by rare diseases. The average time to diagnosis remains 5.6 years, and 30% of affected children die before the age of five, really highlighting how limited progress has been compared with nearly a decade ago.

In response, the agency is proposing a new licensing pathway designed to accelerate approvals even when clinical data are limited. Under traditional models, drugs are required to complete Phase 3 trials involving hundreds or thousands of patients to demonstrate statistical significance—an expectation that is often mathematically and practically unworkable for rare diseases.

• The Challenge: If a disease only affects 50 people globally, finding 300 for a trial is a non-starter.
• Other Affected Conditions: This challenge isn’t unique to Epidermolysis Bullosa (EB); it stalls progress in Huntington’s Disease, Batten Disease, and ultra-rare pediatric cancers.

The MHRA’s new framework moves toward “Real-World Evidence” (RWE), using data from actual patient use and small “n-of-1” trials to support approval.

Across the Channel: The EU HTA Regulation

The European Union is also consolidating its power through the EU Health Technology Assessment (HTA) Regulation, which has moved into a high-volume phase in 2026.

This regulation introduces Joint Clinical Assessments (JCAs). Previously, a drug maker had to submit 27 different clinical dossiers to 27 different EU countries. Now, a single centralized assessment provides a unified “scientific opinion” on how well a drug works compared to existing ones.

• The Benefit: It prevents “duplication of effort.” Small countries like Estonia or Portugal no longer need to conduct their own massive scientific reviews; they can use the JCA to jump straight to pricing negotiations, drastically reducing the time it takes for a French or German cure to reach a patient in the East.

Regional Struggles and Growth Opportunities

While the science is universal, the struggles are regional. Europe’s rare disease landscape is becoming a map of specialized solutions:

• Germany (Infrastructure): Home to the ZSE (Centres for Rare Diseases) network, Germany is leading the “Digital Health” charge, using AI to scan electronic health records for “red flag” symptoms that doctors might miss.
• France (Data): Through the BNDMR and BAMARA database, France has created one of the world’s largest registries of rare disease data, allowing researchers to track the “natural history” of diseases even without a trial.
• Italy (Clinical Excellence): Italy has historically shown a high prevalence of specific genetic conditions like Thalassemia. Consequently, Italian clusters in Milan and Rome have become global hubs for gene therapy research, challenging the global standard for how blood disorders are managed.
• The Opportunity: The 2026 launch of the European Health Data Space (EHDS) represents a massive growth area. By creating a shared genomic platform, Europe can finally move from “siloed” research to a “federated” model where a researcher in Spain can analyze data from a patient in Sweden without compromising privacy.

Taken together, these national strengths are reshaping where innovation, capital, and partnerships are concentrating. The next phase of growth will favor companies that can operate across systems rather than within a single one—platform developers that integrate diagnostics, genomics, and longitudinal data; therapy developers that design trials around real-world evidence and adaptive endpoints; and health-tech players that can translate fragmented patient signals into regulatory-grade insights. As data interoperability improves through initiatives such as the European Health Data Space, Europe is becoming not just a market for rare disease therapies, but a proving ground for new development, approval, and reimbursement models that could set global precedent.

Europe is moving from a collection of isolated rare disease policies to a coordinated “European Blueprint,” aimed at ensuring the next ten years don’t end with the same 5% statistic.

Author

Bernice Lottering